DE69431212D1 - Behandlung von diabetes - Google Patents

Behandlung von diabetes

Info

Publication number
DE69431212D1
DE69431212D1 DE69431212T DE69431212T DE69431212D1 DE 69431212 D1 DE69431212 D1 DE 69431212D1 DE 69431212 T DE69431212 T DE 69431212T DE 69431212 T DE69431212 T DE 69431212T DE 69431212 D1 DE69431212 D1 DE 69431212D1
Authority
DE
Germany
Prior art keywords
treatment
diabetes
cells
gene
prepograstrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69431212T
Other languages
English (en)
Other versions
DE69431212T2 (de
Inventor
Ronald V Nardi
Stephen J Brand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Waratah Pharmaceuticals Inc
General Hospital Corp
Original Assignee
Waratah Pharmaceuticals Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc, General Hospital Corp filed Critical Waratah Pharmaceuticals Inc
Publication of DE69431212D1 publication Critical patent/DE69431212D1/de
Application granted granted Critical
Publication of DE69431212T2 publication Critical patent/DE69431212T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69431212T 1994-01-24 1994-01-24 Behandlung von diabetes Expired - Fee Related DE69431212T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1993/012055 WO1995019785A1 (en) 1994-01-24 1994-01-24 Treatment for juvenile diabetes

Publications (2)

Publication Number Publication Date
DE69431212D1 true DE69431212D1 (de) 2002-09-26
DE69431212T2 DE69431212T2 (de) 2003-04-10

Family

ID=22237287

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69435212T Expired - Fee Related DE69435212D1 (de) 1994-01-24 1994-01-24 Behandlung von Diabetes
DE69431212T Expired - Fee Related DE69431212T2 (de) 1994-01-24 1994-01-24 Behandlung von diabetes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69435212T Expired - Fee Related DE69435212D1 (de) 1994-01-24 1994-01-24 Behandlung von Diabetes

Country Status (8)

Country Link
EP (4) EP0752882B1 (de)
JP (1) JPH09511384A (de)
AT (1) ATE222503T1 (de)
AU (1) AU7628794A (de)
CA (1) CA2182034C (de)
DE (2) DE69435212D1 (de)
ES (1) ES2185663T3 (de)
WO (1) WO1995019785A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US5885956A (en) 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
DE60039160D1 (de) * 1999-04-06 2008-07-24 Genentech Inc Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
AU2005201435A1 (en) * 1999-04-06 2005-04-28 Genentech, Inc. Use of ErbB receptor ligands in treating diabetes
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
EP1210102B1 (de) * 1999-08-19 2010-04-07 Applied Protein Sciences, LLC Tgf-alpha polypeptide, funktionelle fragmente und methoden zu deren verwendung
JP2004520345A (ja) 2001-01-12 2004-07-08 ワラター・ファーマシューティカルズ・インク 糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続
DE60329724D1 (de) * 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
EP1837031B1 (de) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
EP1648495A2 (de) * 2003-05-27 2006-04-26 Waratah Pharmaceuticals, Inc. Zusammensetzungen mit gastrin und deren verwendung bei diabetes
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US8404637B2 (en) 2005-02-11 2013-03-26 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8409961D0 (en) 1984-04-17 1984-05-31 Searle & Co Pharmaceutical compositions

Also Published As

Publication number Publication date
EP1132091A1 (de) 2001-09-12
DE69435212D1 (de) 2009-07-16
ATE222503T1 (de) 2002-09-15
EP1842552A1 (de) 2007-10-10
CA2182034C (en) 2009-04-21
ES2185663T3 (es) 2003-05-01
AU7628794A (en) 1995-08-08
DE69431212T2 (de) 2003-04-10
EP0752882B1 (de) 2002-08-21
JPH09511384A (ja) 1997-11-18
EP0752882A4 (de) 1999-09-01
EP0752882A1 (de) 1997-01-15
WO1995019785A1 (en) 1995-07-27
CA2182034A1 (en) 1995-07-27
EP1466618A1 (de) 2004-10-13
EP1466618B1 (de) 2009-06-03

Similar Documents

Publication Publication Date Title
ATE222503T1 (de) Behandlung von diabetes
HUP9700368A2 (hu) II-típusú diabetes mellitus kezelése amilin agonistákkal
ES2083851T3 (es) Dispositivo para el tratamiento de cultivos de celulas.
EP0699686A3 (de) Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides
ATE316100T1 (de) Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE69534678D1 (de) Glucagonähnliche Peptide, Zusammensetzungen und Verfahren
DE59811840D1 (de) Zusammensetzung zur therapie von diabetes mellitus und fettsucht
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
DK0686053T3 (da) Apparat til injektion af et farmaceutisk præparat i fast form
DE69100282D1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DK0436469T3 (da) Præparat og fremgangsmåde til behandling af osteoporose i pattedyr
BG101392A (en) Method of treating diabetes mellitus using kgf
DE69431046D1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
WO1996032087A3 (en) Transgenic fish in the treatment of diabetes
DE69939937D1 (de) Translations-kontrollelemente für proteinexpression mit hoher ausbeute in den plastiden von höheren pflanzen und verfahren zu deren verwendung
HU9700598D0 (en) Process for profilacting and treating pancreatitis
AU2158688A (en) Use of bezafibrate for treating diabetes
DE59801891D1 (de) Verfahren zum thermischen behandeln von flüchtige, brennbare bestandteile enthaltendem material
KR890700752A (ko) 연료분사량 제어를 위한 장치 및 그 방법
ATE192656T1 (de) Verfahren zur behandlung von patienten mit chronischer lebererkrankung
AU4908385A (en) Priming and purging blood treatment apparatus
DE68916135D1 (de) Verfahren zur Behandlung von verbrauchtem Brennstoff.
DE59509173D1 (de) Verwendung von BK-RiV-Präparaten als Arzneimittel zur Therapie von AIDS
MX9710291A (es) Inhibidores ligantes de proteinas de fijacion con factor de crecimiento del tipo de insulina y metodos de uso para los mismos.
NO871554L (no) Fremgangsmaate og apparat for paavisning av hydrogenholdigeeller hydrogenreaktive gasser.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee